Black Diamond Therapeutics, Inc. (BDTX)

NMS – Real vaqt narxi. Valyuta: USD

2.85

+0.02 (0.71%)

Bozor ochiq: May 13, 2026, 10:31 AM EDT

11.05.2026

BDTX Shares Gain 11% in a Week: Here's What You Should Know

Black Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and continued progress for lead candidate silevertinib.

07.05.2026

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual Meeting First patient dosed in the Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII+ GBM Cash, cash equivalents, and investments of $118.3 million as of March 31, 2026, expected to be sufficient to fund operations into 2H of 2028 CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.

28.04.2026

Implied Volatility Surging for Black Diamond Therapeutics Stock Options

Investors need to pay close attention to BDTX stock based on the movements in the options market lately.

23.04.2026

BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right

Black Diamond Therapeutics hinges on silevertinib, with 2026 data on progression-free survival and durability set to determine whether its single-asset story can justify upside.

23.04.2026

BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize

Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market.

23.04.2026

Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks

BDTX rides on silevertinib, with 2026 durability data set to test early NSCLC efficacy and CNS signals, making upcoming readouts a decisive swing factor.

21.04.2026

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 – June 2, 2026, in Chicago.

Black Diamond Therapeutics, Inc. (BDTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Black Diamond Therapeutics, Inc. (BDTX)

BDTX Shares Gain 11% in a Week: Here's What You Should Know

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Implied Volatility Surging for Black Diamond Therapeutics Stock Options

BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right

BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize

Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

BDTX Shares Gain 11% in a Week: Here's What You Should Know

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Implied Volatility Surging for Black Diamond Therapeutics Stock Options

BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right

BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize

Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

Videolar

No Data

Press-relizlar

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Search stocks

Black Diamond Therapeutics, Inc. (BDTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Black Diamond Therapeutics, Inc. (BDTX)

BDTX Shares Gain 11% in a Week: Here's What You Should Know

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Implied Volatility Surging for Black Diamond Therapeutics Stock Options

BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right

BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize

Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

BDTX Shares Gain 11% in a Week: Here's What You Should Know

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Implied Volatility Surging for Black Diamond Therapeutics Stock Options

BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right

BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize

Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

Videolar

No Data

Press-relizlar

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM